Nutra Pharma Corp., a biotechnology holding company that owns rights to intellectual property related to the development of drugs for Multiple Sclerosis and HIV, has announced that its minority holding, ReceptoPharm, Inc., has completed a study of RPI-MN indicating that the drug is effective against drug-resistant strains of HIV. RPI-MN is the leading anti-viral drug candidate of ReceptoPharm, Inc. and is being studied in preclinical assays for its efficacy in treating HIV/AIDS.
The ability of the HIV virus to establish resistance to therapeutic drugs through genetic mutation is a major concern in the treatment of HIV/AIDS. HIV does not always make perfect copies of itself. With billions of viruses being made every day, lots of small, random differences can occur. The differences are called mutations and these mutations can prevent drugs from working effectively. When a drug no longer works against HIV, this is called drug resistance and the virus with the mutation is considered to be 'resistant' to the drug. With the increasing number of drug-resistant patients, it is of great importance in the development of new HIV/AIDS therapeutics that they will be effective against HIV of known resistance characteristics.
"RPI-MN has already been proven to have broad antiviral activity and a well established safety record in humans," commented Paul Reid, PhD, ReceptoPharm's CEO. "Recent laboratory studies revealed that RPI-MN was capable of inhibiting the replication of HIV as efficiently as normal or wild-type strains. This current study showing efficacy against resistant strains of the virus may allow us to quickly move into human clinical trials," he concluded.
The inhibition of multi-resistant HIV-1 strains by RPI-MN preparations was investigated at the La Jolla Institute of Molecular Medicine. The activity was assessed by recombinant virus assays using a chimeric HIV CCR5 isolate containing known genetic mutations and the Renilla luciferase gene. RPI-MN inhibited drug resistant strains with a similar potency as wild type strains. The drug resistance determinants examined were those from Reverse Transcriptase (RT), Protease and fusion inhibitors. Some strains contained dual resistance to RT and Protease inhibitors with as many 23 distinct mutants. It is anticipated that this data will accelerate the move into clinical trials with subjects infected with HIV.
"Nutra Pharma is excited by the results of this study," commented Rik Deitsch, Nutra Pharma's CEO. "Knowing that RPI-MN has such a great impact on resistant strains of HIV may help in the drug's progression through clinical trials and eventual approval," he added.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The study with RPI-MN that indicated that the drug is effective against drug-resistant strains of HIV should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.